Stuart Rich - Jun 9, 2022 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Chief Medical Officer, Director, 10%+ Owner
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Stock symbol
TENX
Transactions as of
Jun 9, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 09:34 PM
Previous filing
Dec 6, 2021
Next filing
Sep 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TENX Common Stock 2.33M Jun 9, 2022 Direct
holding TENX Common Stock 1.91M Jun 9, 2022 By Andrea Rich 2021 Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +100K $0.00 100K Jun 9, 2022 Common Stock 100K $0.62 Direct F2
holding TENX Stock Option (right to buy) 250K Jun 9, 2022 Common Stock 250K $1.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is co-trustee of the Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2 The options vest and become exercisable as follows: options with respect to 25,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F3 The option becomes exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.